Collection and Analysis of the Clinical and Biological Characteristics of Patients Treated for Giant Cells ARTEitis (Horton's Disease)
NCT ID: NCT04142515
Last Updated: 2022-09-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
83 participants
OBSERVATIONAL
2020-02-01
2021-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Treatment: corticosteroid therapy, which is effective in the vast majority of cases.
Clinical problem: relapse; 36% to 44% of patients have a relapse that occurs in the first year for many patients, requiring a re-escalation of corticosteroid therapy, with its consequences:
* Cumulative dose of corticosteroid therapy that causes cardiovascular and infectious morbidity.
* Requires additional immunosuppressive treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers in Giant Cells Arteritis
NCT02844023
Association of Ultrasonographic Temporal Artery Lesions and Relapse in Patients With Giant Cell Arteritis
NCT06894602
Giant Cell Arteritis: Comparison Between Two Standardized Corticosteroids Tapering
NCT04012905
Tocilizumab for Patients With Giant Cell Arteritis
NCT01450137
Bosentan in the Treatment of Giant Cell Arteritis
NCT06957002
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
no intervention
no intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with giant cell arteritis according to ACR criteria or revised criteria incorporating imaging parameters,
* Patients managed at the University Hospital of Carémeau in Internal Medicine from 01/01/2011 to 01/01/2020.
Exclusion Criteria
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nīmes
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHUNimes
Nîmes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Local2019/RG-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.